IL-17 inhibitors for psoriasis

Semin Cutan Med Surg. 2018 Sep;37(3):148-157. doi: 10.12788/j.sder.2018.051.

Abstract

The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Dermatologic Agents / adverse effects
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Psoriasis / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Interleukin-17
  • brodalumab
  • ixekizumab
  • secukinumab